Mwyngil Therapeutics Announces Positive in vivo Proof of Concept Data for First-in-Class GPR75 Inverse Agonist in Obesity and Cardiometabolic Disease.
Lead oral compounds demonstrated up to 25% body weight reduction with preferential fat loss, preserved lean mass, and broad metabolic improvements in DIO models BOSTON, June 25, 2026 /PRNewswire/ -- Mwyngil Therapeutics, a biotech company focused on developing innovative small molecule...
Lead oral compounds demonstrated up to 25% body weight reduction with preferential fat loss, preserved lean mass, and broad metabolic improvements in DIO models BOSTON, June 25, 2026 /PRNewswire/ -- Mwyngil Therapeutics, a biotech company focused on developing innovative small molecule...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.